4B Technologies was selected into the final list of KPMG China Future Sector 50 Ranking Series—Biotech

4B Technologies was selected into the final list of KPMG China Future Sector 50 Ranking Series—Biotech

4B Technologies’ category 1 innovative monoclonal antibody drug approved for clinical trial

On March 20, 2023, FB1001 has been granted clinical trial approval by CDE

The Phase I clinical trial Kick-Off Meeting of FB-1071 for the treatment of ALS Successfully Held in Shanghai

On March 1st, 2023, the Phase I clinical trial Kick-Off Meeting of FB-1071, a category 1 new drug of 4B Technologies, was successfully held in Huashan Hospital affiliated...